Hyderabad News Desk

DelveInsight’s “Ocular Hypertension Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Ocular Hypertension, historical and forecasted epidemiology as well as the Ocular Hypertension market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Ocular Hypertension market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Ocular Hypertension Market Forecast

Some of the key facts of the Ocular Hypertension Market Report: 

• The Ocular Hypertension market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In the 7MM, there were almost 21,104,768 cases of Ocular Hypertension overall in the year 2022. In the 7MM, the US had the greatest number of prevalent cases in 2022; by 2032, it is expected that this number will rise even more
• Among EU4 and the UK, which accounted for approximately 8,258,082 cases in 2022, Germany had the highest prevalence of OHT with approximately 2,154,448 cases, while Spain had the least prevalence with 1,428,018 cases in 2022
• Among the promising new medicines are PDP-716 (Visiox Pharma), Nyxol (Ocuphire Pharma), LL-BMT1 (MediPrint Ophthalmics), NCX 470 (Nicox Ophthalmics), and Sepetaprost (DE-126/ONO-9054) (Santen/Ono Pharmaceutical). In the next years, they should alter the Ocular Hypertension market environment
• Key Ocular Hypertension Companies: Nicox Ophthalmics, Ocuphire Pharma, Santen Inc, Ono Pharmaceutical, MediPrint Ophthalmics, Visiox Pharma, Sun Pharma Advanced Research Company, Danube Pharmaceuticals, Inc., Aerie Pharmaceuticals, Bausch & Lomb Incorporated, Futuremedicine, Allergan, Samil Pharmaceutical, Inotek Pharmaceuticals, Novartis, Mati Therapeutics Inc., and others
• Key Ocular Hypertension Therapies: NCX 470, Nyxol, Sepetaprost(DE-126/ONO-9054/STN1012600 ), LL-BMT1, PDP-716, DNB-001, AR-12286, Latanoprostene Bunod, FM101, bimatoprost, Xalatan, INO-8875, RKI983A, Latanoprost-PPDS, and others
• The Ocular Hypertension epidemiology based on gender analyzed that females are more affected than males
• The Ocular Hypertension market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Ocular Hypertension pipeline products will significantly revolutionize the Ocular Hypertension market dynamics.

Ocular Hypertension Overview

When there is no clinical indication of optic nerve damage or a visual field impairment, intraocular pressure (IOP) higher than 21 mm Hg in one or both eyes is referred to as ocular hypertension (OHT). Ocular hypertension (OHT) is the primary risk factor for glaucoma development, hence those with OHT have an increased likelihood of acquiring the condition.

Get a Free sample for the Ocular Hypertension Market Report 

https://www.delveinsight.com/report-store/ocular-hypertension-market

Ocular Hypertension Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Ocular Hypertension Epidemiology Segmentation:

The Ocular Hypertension market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Ocular Hypertension
• Prevalent Cases of Ocular Hypertension by severity
• Gender-specific Prevalence of Ocular Hypertension
• Diagnosed Cases of Episodic and Chronic Ocular Hypertension

Download the report to understand which factors are driving Ocular Hypertension epidemiology trends @ Ocular Hypertension Epidemiology Forecast

Ocular Hypertension Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Ocular Hypertension market or expected to get launched during the study period. The analysis covers Ocular Hypertension market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Ocular Hypertension Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Ocular Hypertension Therapies and Key Companies

• NCX 470: Nicox Ophthalmics
• Nyxol: Ocuphire Pharma
• Sepetaprost(DE-126/ONO-9054/STN1012600 ): Santen Inc. /Ono Pharmaceutical
• LL-BMT1: MediPrint Ophthalmics
• PDP-716: Visiox Pharma/ Sun Pharma Advanced Research Company
• DNB-001: Danube Pharmaceuticals, Inc.
• AR-12286: Aerie Pharmaceuticals
• Latanoprostene Bunod: Bausch & Lomb Incorporated
• FM101: Futuremedicine
• bimatoprost: Allergan
• Xalatan: Samil Pharmaceutical
• INO-8875: Inotek Pharmaceuticals
• RKI983A: Novartis
• Latanoprost-PPDS: Mati Therapeutics Inc.

Discover more about therapies set to grab major Ocular Hypertension market share @ Ocular Hypertension Treatment Market

Scope of the Ocular Hypertension Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Ocular Hypertension Companies: Nicox Ophthalmics, Ocuphire Pharma, Santen Inc, Ono Pharmaceutical, MediPrint Ophthalmics, Visiox Pharma, Sun Pharma Advanced Research Company, Danube Pharmaceuticals, Inc., Aerie Pharmaceuticals, Bausch & Lomb Incorporated, Futuremedicine, Allergan, Samil Pharmaceutical, Inotek Pharmaceuticals, Novartis, Mati Therapeutics Inc., and others
• Key Ocular Hypertension Therapies: NCX 470, Nyxol, Sepetaprost(DE-126/ONO-9054/STN1012600 ), LL-BMT1, PDP-716, DNB-001, AR-12286, Latanoprostene Bunod, FM101, bimatoprost, Xalatan, INO-8875, RKI983A, Latanoprost-PPDS, and others
• Ocular Hypertension Therapeutic Assessment: Ocular Hypertension current marketed and Ocular Hypertension emerging therapies
• Ocular Hypertension Market Dynamics: Ocular Hypertension market drivers and Ocular Hypertension market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Ocular Hypertension Unmet Needs, KOL’s views, Analyst’s views, Ocular Hypertension Market Access and Reimbursement 

To know more about Ocular Hypertension companies working in the treatment market, visit @ Ocular Hypertension Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Ocular Hypertension Market Report Introduction

2. Executive Summary for Ocular Hypertension

3. SWOT analysis of Ocular Hypertension

4. Ocular Hypertension Patient Share (%) Overview at a Glance

5. Ocular Hypertension Market Overview at a Glance

6. Ocular Hypertension Disease Background and Overview

7. Ocular Hypertension Epidemiology and Patient Population

8. Country-Specific Patient Population of Ocular Hypertension 

9. Ocular Hypertension Current Treatment and Medical Practices

10. Ocular Hypertension Unmet Needs

11. Ocular Hypertension Emerging Therapies

12. Ocular Hypertension Market Outlook

13. Country-Wise Ocular Hypertension Market Analysis (2019–2032)

14. Ocular Hypertension Market Access and Reimbursement of Therapies

15. Ocular Hypertension Market Drivers

16. Ocular Hypertension Market Barriers

17.  Ocular Hypertension Appendix

18. Ocular Hypertension Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services